KRSA
What one share of Cyclerion Therapeutics holds
Pharmaceutical Preparations
We focus on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Our current strategic focus is centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (“TRD”), which we believe represents a substantial clinical and commercial opportunity.
Cyclerion Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.49 |
|---|---|
| Profit | −$1.73 |
| Cash and investments | $0.33 |
| Book value | $1.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1.68 | $0.05 | −$1.47 | — | — |
| 2019 | $0.07 | −$1.80 | $0.10 | −$1.59 | — | $1.42 |
| 2020 | $0.03 | −$1.02 | $0.02 | −$0.97 | — | $0.70 |
| 2021 | $0.04 | −$0.53 | $0.00 | −$0.37 | — | $0.44 |
| 2022 | $0.14 | −$20.28 | $0.00 | −$18.69 | — | $4.80 |
| 2023 | $0.00 | −$2.25 | — | −$9.09 | — | $4.56 |
| 2024 | $0.79 | −$1.21 | — | −$1.72 | — | $3.48 |
| 2025 | $0.65 | −$1.11 | — | −$1.04 | — | $2.38 |